The Seroconversion Rate of Hepatitis A Virus Vaccination among Patients with Hepatitis B Virus-Related Chronic Liver Disease in Korea.
- Author:
Hyun Chin CHO
1
;
Yu Jin KIM
;
Moon Seok CHOI
;
Joon Hyeok LEE
;
Kwang Cheol KOH
;
Byung Chul YOO
;
Seung Woon PAIK
Author Information
1. Division of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. sw.paik@samsung.com
- Publication Type:Original Article
- Keywords:
Chronic hepatitis B;
Hepatitis B virus related liver cirrhosis;
Hepatitis A virus vaccination
- MeSH:
Antibodies;
Female;
Hepatitis;
Hepatitis A;
Hepatitis A Antibodies;
Hepatitis A virus;
Hepatitis B;
Hepatitis B virus;
Hepatitis B, Chronic;
Humans;
Immunoglobulin G;
Korea;
Liver;
Liver Diseases;
Male;
Vaccination
- From:Gut and Liver
2011;5(2):217-220
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: The aim of this study was to evaluate the seroconversion rate of a hepatitis A virus (HAV) vaccination in patients with hepatitis B virus (HBV)-related chronic liver disease (CLD). METHODS: Analyses were conducted using clinical records from 94 patients with chronic HBV infection who were seronegative for IgG anti-HAV antibodies between September 2008 and June 2009. Two doses of an HAV vaccine were administered 24 weeks apart. A third vaccine dose was administered only for patients seronegative for anti-HAV antibodies at week 48. RESULTS: The seroconversion rate of anti-HAV following the two-dose vaccination was 86.17%. The seroconversion rate of anti-HAV was not significantly different according to age or status of liver disease. The rate was higher in female than in male patients. A third HAV vaccine dose was administered to 13 patients seronegative for anti-HAV after the two-dose regimen, and 84.62% of these patients showed seroconversion at week 72. CONCLUSIONS: HAV vaccination is effective in most Korean patients with HBV-related CLD, and it might be necessary to evaluate three-dose vaccination approach for non-responders to the conventional regimen to maximize the success of an HAV vaccination program.
